RTP Mobile Logo
Cancer Conference Update, Issue 2, 2012
Released September 2012

Featuring interviews with Drs Keith T Flaherty, Charles S Fuchs, Eric P Winer, Daniel J George, Edward S Kim, A Keith Stewart, Jonathan W Friedberg, Hagop M Kantarjian and Jonathan A Ledermann. (Audio Content)

CE Disclosures and Faculty Information

  • OVERVIEW OF ACTIVITY

    Oncology is one of the most rapidly evolving fields in medicine. Results presented at major cancer conferences from a myriad of ongoing clinical trials lead to the continual emergence of new therapeutic agents and changes in the indications for existing treatments. In order to offer optimal patient care, medical oncologists and hematologists must be well informed of these advances. To bridge the gap between research and clinical practice, this issue of Cancer Conference Update features one-on-one discussions with Drs Flaherty, Fuchs, Winer, George, Kim, Stewart, Friedberg, Kantarjian and Ledermann about the integration of key data sets presented at the 2012 American Society of Clinical Oncology Annual Meeting in Chicago, Illinois into the practical management of a number of solid tumors and hematologic cancers.

    LEARNING OBJECTIVES

    • Refine current and future treatment approaches for advanced BRAF-mutant melanoma based on updated results with approved agents and newly emergent data with investigational agents.
    • Evaluate the safety and activity of cancer immunotherapies targeting the PD-1/PD-L1 pathway in melanoma and lung and renal cell cancers.
    • Assess the practical implications of novel anti-VEGF strategies and agents in the treatment of metastatic colorectal cancer.
    • Reconsider the therapeutic algorithm for patients with advanced HER2-positive breast cancer based on recently reported new and pivotal clinical trial results.
    • Incorporate emerging clinical research with androgen-targeted therapy and bone-targeted agents in the treatment approach for hormone-sensitive and castration-resistant metastatic prostate cancer.
    • Employ individualized patient assessment to tailor the use of cytotoxic, biologic and/or small-molecule targeted therapy for non-small cell lung cancer.
    • Incorporate emerging research information on the use of novel schedules, regimens and agents into the systemic treatment of various hematologic cancers.
    • Assess the relevance of emerging research information on PARP inhibitors and anti-angiogenic therapies in current protocol and nonprotocol management of advanced ovarian cancer.

    ACCREDITATION STATEMENT

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CREDIT DESIGNATION STATEMENT

    Research To Practice designates this enduring material for a maximum of 4 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    HOW TO USE THIS CME ACTIVITY

    This CME activity contains an audio component. To receive credit, the participant should listen to the audio MP3s, complete the Post-test with a score of 75% or better and fill out the Educational Assessment and Credit Form located on our website at ResearchToPractice.com/CACU212/CME.

    CONTENT VALIDATION AND DISCLOSURES

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr FlahertyAdvisory Committee: Boehringer Ingelheim Pharmaceuticals Inc, Eisai Inc, GlaxoSmithKline, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Sanofi; Consulting Agreements: Genentech BioOncology, GlaxoSmithKline, Roche Laboratories Inc. Dr FuchsAdvisory Committee: Amgen Inc, Bristol-Myers Squibb Company, Genentech BioOncology, Genomic Health Inc, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Pfizer Inc, Roche Laboratories Inc, Sanofi; Consulting Agreements: Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech BioOncology, Genomic Health Inc, GlaxoSmithKline, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Pfizer Inc, Roche Laboratories Inc, Sanofi. Dr WinerAdvisory Committee: Novartis Pharmaceuticals Corporation. Dr GeorgeAdvisory Committee: Medivation Inc, Sanofi, Viamet Pharmaceuticals Inc; Consulting Agreements: Bayer HealthCare Pharmaceuticals, Dendreon Corporation, Genentech BioOncology, Ipsen, Janssen Pharmaceuticals Inc, Medivation Inc, Novartis Pharmaceuticals Corporation, Pfizer Inc, Sanofi; Paid Research: Bristol-Myers Squibb Company, Dendreon Corporation, Exelixis Inc, Genentech BioOncology, GlaxoSmithKline, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Ipsen, Janssen Pharmaceuticals Inc, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Pfizer Inc; Speakers Bureau: Dendreon Corporation, Genentech BioOncology, GlaxoSmithKline, Janssen Pharmaceuticals Inc, Novartis Pharmaceuticals Corporation, Pfizer Inc, Sanofi. Dr KimConsulting Agreements: Boehringer Ingelheim Pharmaceuticals Inc, Genentech BioOncology, Lilly USA LLC, OSI Oncology; Paid Research: Genentech BioOncology, Lilly USA LLC. Dr StewartAdvisory Committee: Onyx Pharmaceuticals Inc; Consulting Agreements: Celgene Corporation, Millennium: The Takeda Oncology Company; Paid Research: Millennium: The Takeda Oncology Company, Onyx Pharmaceuticals Inc. Dr FriedbergAdvisory Committee: Seattle Genetics; Consulting Agreement: Genentech BioOncology; Data and Safety Monitoring Board: Lilly USA LLC. Dr KantarjianPaid Research: Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Eisai Inc, Novartis Pharmaceuticals Corporation, Pfizer Inc, Sanofi. Dr LedermannPaid Travel: AstraZeneca Pharmaceuticals LP.

    EDITORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Abbott Laboratories, Allos Therapeutics, Amgen Inc, ArQule Inc, Astellas, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Foundation Medicine Inc, Genentech BioOncology, Genomic Health Inc, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Incyte Corporation, Lilly USA LLC, Medivation Inc, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc and Teva.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.


    This activity is supported by educational grants from Astellas, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Genentech BioOncology, Millennium: The Takeda Oncology Company, Regeneron Pharmaceuticals and Sanofi.

    Hardware/Software Requirements:
    A high-speed Internet connection  
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
    Adobe Flash Player 10.2 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: September 2012
    Expiration date: September 2013

    After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close

Listen to audio:
Cancer Conference Update, Issue 2, 2012
Released September 2012

Featuring interviews with Drs Keith T Flaherty, Charles S Fuchs, Eric P Winer, Daniel J George, Edward S Kim, A Keith Stewart, Jonathan W Friedberg, Hagop M Kantarjian and Jonathan A Ledermann. (Audio Content)

Read print: